8月10日，再鼎医药盘中上涨6.45%，报17.93港元，成交额4528.72万港元。
消息面上，公司于8月6日公布第二季度财务业绩，总收入1.063亿美元，产品收入净额1.058亿美元，环比增长11%，超出市场预期约250万美元。花旗发表报告指出，二季度产品收入环比改善令其更有信心公司中国业务可于下半年企稳，并于明年恢复显著增长。此外，公司核心管线ZOCI即将迎来ESMO数据披露，此前该产品已获欧洲药品管理局孤儿药资格认定及美国FDA快速通道资格认定，市场对其临床数据抱有较高期待。叠加宫颈癌新药缇乐获批上市及精神分裂创新药凯捷乐上市放量，公司商业化组合持续扩充。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.